Exacerbation of Allergic Diseases After COVID-19 Vaccination: A Multicenter Observational Study
Authors:
- Ga-Young BanGBGa-Young Ban
- Hyun Jung JinHJHyun Jung Jin
- Ji-Ho LeeJi-Ho Lee
- Young-Hee NamYNYoung-Hee Nam
- Hyo-In RhyouHRHyo-In Rhyou
- Gil-Soon ChoiGCGil-Soon Choi
- Gyu Young HurGHGyu Young Hur
- Jeong-Hee ChoiJCJeong-Hee Choi
- Joo-Hee KimJKJoo-Hee Kim
- Chang-Gyu JungCJChang-Gyu Jung
- Seong-Dae WooSWSeong-Dae Woo
- Hwa Young LeeHLHwa Young Lee
Open Access
- 16 November 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10277
Abstract
Concerns about worsening allergic disease may contribute to vaccine hesitancy. We evaluated the frequency, severity, and factors associated with self-reported exacerbations after COVID-19 vaccination and described findings after influenza vaccination. In this multicenter observational survey, adults with physician-diagnosed allergic diseases were prospectively enrolled at 14 Korean allergy centers, while vaccination history and post-vaccination outcomes were retrospectively ascertained. Severe exacerbation was defined as requiring emergency department care or hospitalization. Among 1626 COVID-19-vaccinated patients, 281 (17.3%) reported exacerbation; 36 (12.8% of exacerbators; and 2.2% of all vaccinated patients) were severe. Female sex, chronic urticaria, and atopic dermatitis were independently associated with any exacerbation, whereas increasing age and allergic rhinitis were associated with lower odds. Bronchial asthma was independently associated with severe exacerbation (adjusted OR, 3.07; 95% CI, 1.10–8.51). No factor was associated with multiple exacerbations. Biologic therapy and allergen immunotherapy were not associated with increased risk. Exacerbations were reported in 16 of 786 influenza-vaccinated patients (2.0%) and were generally mild. Although self-reported symptom worsening after COVID-19 vaccination was relatively common, severe events were uncommon. COVID-19 vaccination was generally well tolerated, including among patients receiving biologics or allergen immunotherapy.Keywords
Funding Information
- National Research Foundation of Korea (2022R1A2C2006607)
- Ministry of Food and Drug Safety (M-2026-A0632-00001)
This publication has 28 references indexed in Scilit:
- Impact of COVID‐19 disease and vaccination on dermatological immune‐mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudyThe Journal of Dermatology, 2025
- Chronic urticaria: not only after COVID-19 vaccinationCurrent Opinion in Allergy and Clinical Immunology, 2024
- Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based StudyDrug Safety, 2023
- Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU studyJournal of Allergy and Clinical Immunology, 2023
- Incidence of Chronic Spontaneous Urticaria Following Receipt of the COVID-19 Vaccine Booster in SwitzerlandJAMA Network Open, 2023
- COVID-19 vaccines: addressing hesitancy in young people with allergiesThe Lancet Respiratory Medicine, 2021
- The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus ApproachThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Triggers of Exacerbation in Chronic Urticaria and Recurrent Angioedema—Prevalence and RelevanceThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females? – A systematic reviewVaccine, 2020
- Sex differences in immune responsesNature Reviews Immunology, 2016